Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Imperial Innovations Raises 140 Million To Invest In University Spin-Outs

This article was originally published in Start Up

Executive Summary

The AIM-listed tech transfer group Imperial Innovations has raised £140 million to increase its early-stage investments in spin-outs from Imperial College and three other top UK universities

You may also be interested in...



J.P. Morgan Notebook: Wednesday, January 15

We bring you news and notes from the third day of the 2014 J.P. Morgan Healthcare conference, which includes highlights from Genentech, Teva, Sarepta, and new accelerator StartUp Health.

New GSK Spin-Out Targets Hearing Loss

The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.

New GSK Spin-Out Targets Hearing Loss

The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel